Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-20T22:25:01.979Z Has data issue: false hasContentIssue false
  • English
  • Français

1013 – Mild Cognitive Impairment - Pharmacotherapeutic Opportunities

Published online by Cambridge University Press:  15 April 2020

D.M. Podea ,
C. Mila  and
M.M. Blaj
D.M. Podea
Affiliation:
Psychiatric Department, ‘Vasile Goldis’ Western University of Arad, Arad
C. Mila
Affiliation:
Psychiatric Hospital of Mocrea, Mocrea
M.M. Blaj
Affiliation:
Infomedica SRL, Arad, Romania

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Mild cognitive impairment (MCI) is considered today to be a prodromal stage of Alzheimer's dementia, but without standardized pharmacotherapy.

Objectives

To follow the outcome of patients diagnosed with MCI treated with nootropics, alternative herbal agents, cholinesterase inhibitors.

Aims

To assess the efficacy of early treatment in MCI.

Methods

200 patients (over 60 years) diagnosed with MCI were evaluated using the MMSE (Mini Mental State Examination) scale at screening, after 1 and 2 years of treatment. They were divided in four groups:

  • A -50 patients treated with Piracetamum 1600mg/day

  • B -50 patients treated with Rhodiola-rosea, 2capsules/day

  • C -50 patients treated with Galantamine, 16mg/day

  • D -50 patients not treated

Results

The improvement of the MMSE score was as following:

[Results].

MMSE scoreScreeningImprovement after 1 yearImprovement after 2 years
Group A23.962.121.88
Group B24.161.972.28
Group C23.962.142.88
Group D24.5No improvement-2.86 (worsening)

Conclusions

Comparing the outcome of treated and non-treated groups, we observed that the early treatment of MCI delays the transition to dementia. The outcome of the treated groups after 1 year of treatment was approximately the same. Longtime treatment shows a better improvement in the group treated with cholinesterase inhibitors (Galantamine) compared to the other treated groups, but not statistically significant. Galantamine improves cognitive function. This study proves the necessity of early treatment for MCI to delay the transition to dementia.

Type
Abstract
Information
European Psychiatry , Volume 28 , Issue S1: Abstracts of the 21th European Congress of Psychiatry , 2013 , 28-E430
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.